Cardiovascular diseases (CVDs) are the leading cause of premature death and disability in
humans and their incidence is on the rise globally. Given their substantial contribution …

Background: Levels of atherogenic lipoproteins achieved with statin therapy are highly
variable, but the consequence of this variability for cardiovascular disease risk is not well …

Background Pharmacologic inhibitors of proprotein convertase subtilisin–kexin type 9
(PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease …

Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …

Background: Although guidelines recommend in-hospital initiation of high-intensity statin
therapy in patients with acute coronary syndromes (ACS), low-density lipoprotein cholesterol …

The notion that heart attacks develop from coronary-artery stenosis is an oversimplification
of a process involving lipid metabolism, inflammation, macrophage activation, collagen …

Hyperlipidemia is a well-established risk factor for developing cardiovascular disease
(CVD). The recent American College of Cardiology and American Heart Association …

Background Evolocumab, a monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) …

Background: Guidelines recommend statins as first-line therapy for dyslipidemia.
Monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) is a …

Importance In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9,
reduced LDL-C levels in patients receiving statin therapy. Objective To evaluate the efficacy …